News
The recommendation of betula verrucosa is the first NICE approval for an under-the-tongue immunotherapy for these conditions. Unlike conventional treatments that merely mask symptoms, this ...
Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...
The technologies, which have been conditionally recommended in draft guidance, can help detect vertebral fragility fractures (VFFs) on medical images taken for unrelated condition. This means they ...
We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...
Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...
See a complete list of all our guidance and quality standards currently open for consultation ...
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...
Access to a range of journals, databases and other evidence-based resources for health and social care staff in England.
Subscribe to our newsletters, alerts and awareness service. Keep up to date with the latest evidence based information across health and social care.
A quick guide for home care managers providing medicines support Medicines support for adults may be provided by a number of different people, including family, healthcare professionals and homecare ...
Marstacimab is recommended, within its marketing authorisation, as an option for preventing bleeding episodes caused by severe (factor IX [9] activity less than 1%) haemophilia B (congenital factor 9 ...
Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies. Last reviewed: 24 June 2025 Next review: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results